Back to Agenda
The FDA's Clinical Trial Diversity Initiative in the Setting of the Ongoing COVID-19 Pandemic
Session Chair(s)
Wambui Chege, MD, FACP
Physician Policy Advisor, DMPD, OMP, CDER, FDA, United States
FDA’s commitment to Clinical Trial (CT) diversity is integral to the agency’s mission. Recognizing that COVID-19 affects certain populations differently, FDA’s session will explore solutions and stakeholder collaborations in support of CT diversity.
Learning Objective : Recognize how the COVID-19 pandemic underscores the need for clinical trial diversity; Identify ways to increase underrepresented populations in clinical trials in accordance with FDA policy guidance; Evaluate the effectiveness of current FDA policy initiatives aimed at increasing historically underrepresented populations in clinical trials.
Speaker(s)
Richardae Araojo, PHARMD, MS
Associate Commissioner for Minority Health, Director, Office of Minority Health , FDA, United States
Panelist
John Concato, MD, MPH, MS
Associate Director for Real-World Evidence Analytics, OMP, CDER, FDA, United States
Panelist
Peter Basseches, PHD
Distinguished Scientist, Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc, United States
Panelist
Anu Osinusi, MD, MPH
Vice President, Hepatitis, Respiratory and Emerging Viruses, Gilead Sciences, Inc., United States
Panelist
Richard Knight, MBA
President, American Association of Kidney Patients , United States
Panelist
John Whyte, DrMed, MD, MPH
Chief Medical Officer, WebMD, United States
Panelist
Have an account?